Status:
COMPLETED
Study To Examine Effect Of CP-866,087 On Consumption And Craving Of Alcohol In Alcohol Dependent Subjects.
Lead Sponsor:
Pfizer
Conditions:
Alcoholism
Eligibility:
All Genders
21-65 years
Phase:
PHASE2
Brief Summary
Test the hypothesis that increasing doses of CP-866,087 will decrease the total number of drinks consumed during a 2 hour acute alcohol consumption assessment and to determine the safety and tolerabil...
Eligibility Criteria
Inclusion
- Subject meets the DSM-IV criterion for current alcohol dependence.
- Subject is currently not engaged in, and does not want, treatment for alcohol related problems.
Exclusion
- Subject meets criteria for current DSM-IV diagnosis for any other psychoactive substance abuse or dependence disorder, excluding nicotine and caffeine.
- Specialized inpatient or outpatient alcoholism or other addiction treatment (except nicotine) within the past 12 months.
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2004
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT00147576
Start Date
December 1 2003
End Date
December 1 2004
Last Update
October 2 2012
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Cerritos, California, United States, 90703
2
Pfizer Investigational Site
New Haven, Connecticut, United States, 06504
3
Pfizer Investigational Site
New Haven, Connecticut, United States, 06519
4
Pfizer Investigational Site
Washington D.C., District of Columbia, United States, 20016